Visceral leishmaniasis(VL)is a neglected tropical disease,and this review has summarized the current treatment scenario and its prospects.It also highlights alternative approaches used by research groups in India and ...Visceral leishmaniasis(VL)is a neglected tropical disease,and this review has summarized the current treatment scenario and its prospects.It also highlights alternative approaches used by research groups in India and around the world to develop cutting-edge and potent anti-leishmanial treatments.Even though numerous medications could be utilized to treat VL,the limitations of current treatments including their toxicity,cost,route of administration,and duration of doses,have contributed to the emergence of resistance.Combination therapy might be a better option due to its shorter duration,easier route of administration,and ability to extend the lifespan of individual drugs.However,there is a risk of not delivering both the drugs to the target site together,which can be overcome by the liposomal entrapment of those drugs and at a time knock an opportunity to reduce the dosage of amphotericin B if the combination drug provides a synergistic effect with it.Therefore,this review presents a novel strategy to fight against VL by introducing dual drug-loaded liposomes.展开更多
Leishmaniases and chronic inflammatory diseases are the cause of millions of deaths in the world each year.The treatment of leishmaniasis is facing serious drawbacks particularly due to the limited number of effective...Leishmaniases and chronic inflammatory diseases are the cause of millions of deaths in the world each year.The treatment of leishmaniasis is facing serious drawbacks particularly due to the limited number of effective medicines,the resistance,and the toxicity of available drugs.On the other hand,many drugs are used for the management of inflammatory disorders.However,the most commonly prescribed although efficient is highly toxic with multiples side effects.New leads compounds for the development of new anti-leishmanial and anti-inflammatory drugs are needed.Over the past decade,several studies on the potential of endophytes to produce bioactive metabolites have been reported.We are presenting in the present review the status of research from 2000 to 2019 on the anti-leishmanial and anti-inflammatory metabolites isolated from endophytes from diverse habitats.An emphasis was put on existing gaps in the literature to inspire and guide future investigations.We hope that this review will help accelerate the drug discovery against leishmaniases and inflammation-associated disorders.展开更多
基金SKM gratefully acknowledges the support of Indian Council of Medical Research(ICMR),New Delhi,India(File No:6/9-7(308)/2023-ECD-II)RH acknowledges the SVMCM fellowship,West Bengal.
文摘Visceral leishmaniasis(VL)is a neglected tropical disease,and this review has summarized the current treatment scenario and its prospects.It also highlights alternative approaches used by research groups in India and around the world to develop cutting-edge and potent anti-leishmanial treatments.Even though numerous medications could be utilized to treat VL,the limitations of current treatments including their toxicity,cost,route of administration,and duration of doses,have contributed to the emergence of resistance.Combination therapy might be a better option due to its shorter duration,easier route of administration,and ability to extend the lifespan of individual drugs.However,there is a risk of not delivering both the drugs to the target site together,which can be overcome by the liposomal entrapment of those drugs and at a time knock an opportunity to reduce the dosage of amphotericin B if the combination drug provides a synergistic effect with it.Therefore,this review presents a novel strategy to fight against VL by introducing dual drug-loaded liposomes.
文摘Leishmaniases and chronic inflammatory diseases are the cause of millions of deaths in the world each year.The treatment of leishmaniasis is facing serious drawbacks particularly due to the limited number of effective medicines,the resistance,and the toxicity of available drugs.On the other hand,many drugs are used for the management of inflammatory disorders.However,the most commonly prescribed although efficient is highly toxic with multiples side effects.New leads compounds for the development of new anti-leishmanial and anti-inflammatory drugs are needed.Over the past decade,several studies on the potential of endophytes to produce bioactive metabolites have been reported.We are presenting in the present review the status of research from 2000 to 2019 on the anti-leishmanial and anti-inflammatory metabolites isolated from endophytes from diverse habitats.An emphasis was put on existing gaps in the literature to inspire and guide future investigations.We hope that this review will help accelerate the drug discovery against leishmaniases and inflammation-associated disorders.
